U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
A new course at the Azrieli Faculty of Medicine will focus on tissue regeneration and 3D printing for therapeutic needs
Recommendation is based on pivotal data from the phase III POLARIX study
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
This drive will expand access to quality diagnostics and help find the ‘missing millions’ – patients that are suffering from TB but not registered in the healthcare system
The test can overcome the time and cost limitations of traditional culture-based drug susceptibility testing as it can more rapidly detect all mutations known to be associated with drug resistance for any TB drug in one step
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
Subscribe To Our Newsletter & Stay Updated
